Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : GlaxoSmithKline Research & Development Ltd
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray (FFNS) 110 mcg, administered either once daily or twice daily, compared with placebo, as effective monotherapy in the treatment of uncomplicated acute rhinosinusitis (ARS) in adult and adolescent subjects 12 years of age and older
The objective of this study is to evaluate the safety and efficacy of two doses of FFNS (110 mcg once daily and 110 mcg twice daily) compared to placebo as monotherapy in the treatment of adult and ad...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD
The primary objective of this study is to evaluate the dose response, dose interval, efficacy, and safety of GSK961081 by studying three QD doses (100mcg, 400mcg and 800mcg) and three BID doses (100mc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 with tiotropium over 24 weeks in subjects with COPD
The primary objective is to compare the efficacy of two doses of GSK573719/GW642444 Inhalation Powder (125mcg/25mcg and 62.5/25mcg once-daily) with GSK573719 (125mcg once daily) and with tiotropium (1...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations
To evaluate the efficacy and safety of mepolizumab 100 mg subcutaneous (SC) given every 4 weeks compared to placebo on the frequency of moderate and severe exacerbations in COPD subjects at high risk...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
PM1116197 is a Clinical Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo 1. Losmapimod kezelés a p38 kináz, mint terápiás célpont gátlására és az akut koronária-betegséget követő kimenetel módosítására (LATITUDE)-TIMI 60 2. Egy új készítmény vizsgálata szívrohamon átesett betegek kezelésére
The primary objective is to evaluate the efficacy of oral losmapimod 7.5 mg BID compared to placebo when added to standard of care in subjects with ACS on the time to first occurrence of adjudicated M...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder
To evaluate the clinical antidepressant effects of GW856553 versus placebo treatment at Week 6 in adult subjects diagnosed with MDD with symptoms of decreased energy and interest, and with psychomotor...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
Study in subjects with anemia of chronic kidney disease to assess safety and efficacy of daprodustat compared to darbepoetin alfa
•To compare daprodustat to darbepoetin alfa for cardiovascular (CV) safety (non-inferiority) •To compare daprodustat to darbepoetin alfa for hemoglobin (Hgb) efficacy (non-inferiority)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease
• To assess the efficacy of GSK1605786A compared with placebo as an induction therapy in subjects with moderately-to-severely active Crohn’s disease over 12 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
A randomized, double-blind, double-dummy, parallel-group, placebo controlled (on inhaled corticosteroid medication), multicenter study to evaluate the efficacy and safety of vilanterol inhalation powder (GW642444) and salmeterol, compared with placebo in the treatment of persistent asthma in adults and adolescents uncontrolled on inhaled corticosteroids
The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder 25mcg administered once daily in the evening in adolescent and adult subjects 12 years of age and old...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 5 ans
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Exploratory Study to Evaluate the Effect of Adding GSK2190915 300mg Tablets Once Daily, Montelukast 10mg Tablets Once Daily or Placebo Tablets Once Daily to Fluticasone Propionate 250mcg/Salmeterol 50mcg Inhalation Powder Twice Daily in Uncontrolled Asthmatic Subjects > 18 Years of Age
Evaluate the efficacy and safety of adding GSK2190915 300mg or placebo tablets administered once daily to FP/SAL 250/50mcg inhalation powder administered twice daily in uncontrolled asthmatic subjects...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
1
2
3
4
5
6
7
8
9
10
Suivant